|Mr. Jonathan Royce||Chief Exec. Officer||N/A||N/A||N/A|
|Mr. Jan BerglÃ¶f||Co-Founder & Sr. Advisor||N/A||N/A||N/A|
|Mr. Tord Kallioniemi||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Karsten FjÃ¤rstedt||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Line Thomson||People & Culture||N/A||N/A||N/A|
|Ms. Helena Pahlm||Sr. Director of Global Quality||N/A||N/A||N/A|
Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.
Bio-Works Technologies AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.